董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robin D. Campbell | 男 | Director | 70 | 17.77万美元 | 未持股 | 2020-03-02 |
| John M. Taylor | 男 | Director | 60 | 3.13万美元 | 未持股 | 2020-03-02 |
| Evert B. Schimmelpennink | 男 | Chief Executive Officer, President, Secretary, Chief Financial Officer and Director | 48 | 未披露 | 未持股 | 2020-03-02 |
| Jason Grenfell Gardner | -- | Chairman and Director | -- | 未披露 | 未持股 | 2020-03-02 |
| Magda Marquet | -- | Director | -- | 未披露 | 未持股 | 2020-03-02 |
| Lorianne Masuoka | -- | Director | -- | 未披露 | 未持股 | 2020-03-02 |
| Phillip M. Schneider | 男 | Director | 68 | 18.44万美元 | 未持股 | 2020-03-02 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Evert B. Schimmelpennink | 男 | Chief Executive Officer, President, Secretary, Chief Financial Officer and Director | 48 | 未披露 | 未持股 | 2020-03-02 |
| Shawn A. Scranton | 男 | Chief Operating Officer | 56 | 未披露 | 未持股 | 2020-03-02 |
| Martin B. Brenner | 男 | Chief Scientific Officer | 49 | 未披露 | 未持股 | 2020-03-02 |
| Patrick K. Lucy | 男 | Chief Business Officer | 52 | 81.37万美元 | 未持股 | 2020-03-02 |
董事简历
中英对照 | 中文 | 英文- Robin D. Campbell
-
Robin D. Campbell，2014年加入我们的董事会。自2009以来，Campbell博士曾担任位于圣巴巴拉的加利福尼亚大学的技术管理课程讲师。从2008年到2012年，坎贝尔博士担任Campbell Management Solutions, LLC（战略和管理咨询公司）的总经理。2004年到2008年他担任Naryx Pharma, Inc（一家制药公司）总裁兼首席执行官；1989年到2002年他担任Amgen, Inc（一家生物制药公司）不同的管理职位，包括美国肿瘤业务总经理、亚太地区总经理和拉丁美洲业务副总裁；1997年到2000年，他担任。Kirin-Amgen, Inc.（一家Kirin Brewery Company, Limited和Amgen, Inc合资的生物技术企业）的总裁；1998年到1999年，他是SEQUUS Pharmaceuticalssequus（一个癌症药物上市公司）董事会成员。他目前是Aptitude Medical Systems（一个私人的研究平台技术公司）的董事会主席。他拥有位于教堂山的北卡罗来那大学动物学学士学位以及维克森林大学微生物学和免疫学博士学位。
Robin D. Campbell joined our board of directors in 2014. Dr. Campbell has served as a Technology Management Program Lecturer at the University of California, Santa Barbara since 2009. From 2008 to 2012 Dr. Campbell served as Managing Director of Campbell Management Solutions, LLC, a strategy and management consulting company. Prior to that, Dr. Campbell served as President and Chief Executive Officer of Naryx Pharma, Inc., a pharmaceutical company, from 2004 to 2008. From 1989 to 2002 Dr. Campbell held various management positions with Amgen, Inc., a biopharmaceutical company, including Vice President of the U.S. Oncology Business Unit and General Manager and Vice President of Asia Pacific and Latin American Operations. Dr. Campbell served as President of Kirin-Amgen, Inc., a biotechnology joint venture between Kirin Brewery Company, Limited and Amgen, Inc., from 1997 to 2000. Dr. Campbell served on the board of directors of SEQUUS Pharmaceuticals, a public oncology therapeutics company, from 1998 to 1999. Dr. Campbell is currently the Chairman of the Board of Aptitude Medical Systems, a private research platform technology company, and a member of the Board of Directors of Acelot, Inc., a private bioinformatics drug discovery platform company. Dr. Campbell holds a Bachelor's degree in Zoology from the University of North Carolina, Chapel Hill and a Ph.D. in Microbiology and Immunology from Wake Forest University. - Robin D. Campbell，2014年加入我们的董事会。自2009以来，Campbell博士曾担任位于圣巴巴拉的加利福尼亚大学的技术管理课程讲师。从2008年到2012年，坎贝尔博士担任Campbell Management Solutions, LLC（战略和管理咨询公司）的总经理。2004年到2008年他担任Naryx Pharma, Inc（一家制药公司）总裁兼首席执行官；1989年到2002年他担任Amgen, Inc（一家生物制药公司）不同的管理职位，包括美国肿瘤业务总经理、亚太地区总经理和拉丁美洲业务副总裁；1997年到2000年，他担任。Kirin-Amgen, Inc.（一家Kirin Brewery Company, Limited和Amgen, Inc合资的生物技术企业）的总裁；1998年到1999年，他是SEQUUS Pharmaceuticalssequus（一个癌症药物上市公司）董事会成员。他目前是Aptitude Medical Systems（一个私人的研究平台技术公司）的董事会主席。他拥有位于教堂山的北卡罗来那大学动物学学士学位以及维克森林大学微生物学和免疫学博士学位。
- Robin D. Campbell joined our board of directors in 2014. Dr. Campbell has served as a Technology Management Program Lecturer at the University of California, Santa Barbara since 2009. From 2008 to 2012 Dr. Campbell served as Managing Director of Campbell Management Solutions, LLC, a strategy and management consulting company. Prior to that, Dr. Campbell served as President and Chief Executive Officer of Naryx Pharma, Inc., a pharmaceutical company, from 2004 to 2008. From 1989 to 2002 Dr. Campbell held various management positions with Amgen, Inc., a biopharmaceutical company, including Vice President of the U.S. Oncology Business Unit and General Manager and Vice President of Asia Pacific and Latin American Operations. Dr. Campbell served as President of Kirin-Amgen, Inc., a biotechnology joint venture between Kirin Brewery Company, Limited and Amgen, Inc., from 1997 to 2000. Dr. Campbell served on the board of directors of SEQUUS Pharmaceuticals, a public oncology therapeutics company, from 1998 to 1999. Dr. Campbell is currently the Chairman of the Board of Aptitude Medical Systems, a private research platform technology company, and a member of the Board of Directors of Acelot, Inc., a private bioinformatics drug discovery platform company. Dr. Campbell holds a Bachelor's degree in Zoology from the University of North Carolina, Chapel Hill and a Ph.D. in Microbiology and Immunology from Wake Forest University.
- John M. Taylor
-
John M. Taylor ，他是提名董事。他曾一直担任Greenleaf Health公司（咨询公司，向FDA相关企业提供战略指导）的负责合规和监管事务的负责人（2014年9月以来）。加入Greenleaf公司之前，他曾担任美国食品和药物管理局（the U.S. Food and Drug Administration，FDA）的专员顾问、代理副首席专员、全球监管业务和政策代理副专员（从2009年10月到2014年2月）。此前，他曾担任the Biotechnology Industry Organization （BIO）（生物技术组织，提供宣传、业务发展和通讯服务）的健康执行副总裁（从2007年到2009年）。加入BIO公司之前，他曾担任Abbott Laboratories公司（一个多元化的医疗保健公司）的负责联邦政府事务的区域副总裁（从2005年到2007年）。加入Abbott公司之前，他曾担任FDA公司的多种职务，法规事务副专员（从2002年到2005年）、执法办公室董事（从2000年到2002年）、合规药物评价和研究中心办公室代理董事（2000年）、监管事务副专员的特殊助理（1999年）、监管政策专员办公室的特殊顾问（从1996年到1999年）、首席顾问办公室的律师（从1991年到1996年）。他获得Pennsylvania State University的荣誉学士学位，以及the College of William and Mary的法学博士学位。
John M. Taylor is a nominee for director. Mr. Taylor has served since September of 2014 as the Principal of Compliance and Regulatory Affairs of Greenleaf Health, LLC, a consulting firm that provides strategic guidance to FDA-regulated companies. Prior to joining Greenleaf, Mr. Taylor served as Counselor to the Commissioner, Acting Deputy Principal Commissioner, and Acting Deputy Commissioner for Global Regulatory Operations and Policy at the U.S. Food and Drug Administration FDA from October of 2009 to February of 2014. Prior to that, Mr. Taylor served as the Executive Vice President for Health at the Biotechnology Industry Organization (BIO), a biotechnology organization providing advocacy, business development and communications services, from 2007 to 2009. Prior to joining BIO, Mr. Taylor served as Divisional Vice President for Federal Government Affairs at Abbott Laboratories, a diversified healthcare company, from 2005 to 2007. Prior to joining Abbott, Mr. Taylor served at the FDA in a variety of positions, as Associate Commissioner for Regulatory Affairs from 2002 to 2005 Director of the Office of Enforcement from 2000 to 2002 Acting Director of the Office of Compliance in the Center for Drug Evaluation and Research in 2000 Special Assistant to the Associate Commissioner for Regulatory Affairs in 1999 Senior Advisor for Regulatory Policy within the Office of the Commissioner from 1996 to 1999 and as an Attorney in the Office of the Chief Counsel from 1991 to 1996. Mr. Taylor holds a Bachelor’s degree in History from Pennsylvania State University and a J.D. from the College of William and Mary. - John M. Taylor ，他是提名董事。他曾一直担任Greenleaf Health公司（咨询公司，向FDA相关企业提供战略指导）的负责合规和监管事务的负责人（2014年9月以来）。加入Greenleaf公司之前，他曾担任美国食品和药物管理局（the U.S. Food and Drug Administration，FDA）的专员顾问、代理副首席专员、全球监管业务和政策代理副专员（从2009年10月到2014年2月）。此前，他曾担任the Biotechnology Industry Organization （BIO）（生物技术组织，提供宣传、业务发展和通讯服务）的健康执行副总裁（从2007年到2009年）。加入BIO公司之前，他曾担任Abbott Laboratories公司（一个多元化的医疗保健公司）的负责联邦政府事务的区域副总裁（从2005年到2007年）。加入Abbott公司之前，他曾担任FDA公司的多种职务，法规事务副专员（从2002年到2005年）、执法办公室董事（从2000年到2002年）、合规药物评价和研究中心办公室代理董事（2000年）、监管事务副专员的特殊助理（1999年）、监管政策专员办公室的特殊顾问（从1996年到1999年）、首席顾问办公室的律师（从1991年到1996年）。他获得Pennsylvania State University的荣誉学士学位，以及the College of William and Mary的法学博士学位。
- John M. Taylor is a nominee for director. Mr. Taylor has served since September of 2014 as the Principal of Compliance and Regulatory Affairs of Greenleaf Health, LLC, a consulting firm that provides strategic guidance to FDA-regulated companies. Prior to joining Greenleaf, Mr. Taylor served as Counselor to the Commissioner, Acting Deputy Principal Commissioner, and Acting Deputy Commissioner for Global Regulatory Operations and Policy at the U.S. Food and Drug Administration FDA from October of 2009 to February of 2014. Prior to that, Mr. Taylor served as the Executive Vice President for Health at the Biotechnology Industry Organization (BIO), a biotechnology organization providing advocacy, business development and communications services, from 2007 to 2009. Prior to joining BIO, Mr. Taylor served as Divisional Vice President for Federal Government Affairs at Abbott Laboratories, a diversified healthcare company, from 2005 to 2007. Prior to joining Abbott, Mr. Taylor served at the FDA in a variety of positions, as Associate Commissioner for Regulatory Affairs from 2002 to 2005 Director of the Office of Enforcement from 2000 to 2002 Acting Director of the Office of Compliance in the Center for Drug Evaluation and Research in 2000 Special Assistant to the Associate Commissioner for Regulatory Affairs in 1999 Senior Advisor for Regulatory Policy within the Office of the Commissioner from 1996 to 1999 and as an Attorney in the Office of the Chief Counsel from 1991 to 1996. Mr. Taylor holds a Bachelor’s degree in History from Pennsylvania State University and a J.D. from the College of William and Mary.
- Evert B. Schimmelpennink
-
EvertB.Schimmelpennink自2017年8月起担任我们的首席执行官，总裁兼秘书，自2019年11月起担任我们的首席财务官。在被任命之前，Schimmelpennink先生于2015年至2017年7月担任生物仿制药开发公司Alvotech的首席执行官。2015年9月至2015年11月，Schimmelpennink先生担任制药公司辉瑞公司的Vice President-全球无菌注射剂。在此之前，Schimmelpennink先生于2012年至2015年担任Vice President-Global Generics，并于2011年至2012年担任制药公司好比拉医疗保健公司的特殊注射药物营销EMEA总监和分销商运营EMEA总监。Schimmelpennink从2002年到2011年在Synthon BV（一家仿制药公司）担任多个职位，包括从2008年到2011年担任Vice President市场营销与销售。从1997年到2002年，他曾担任Numico NV公司（荷兰婴儿食品和营养棒和奶昔制造商）的多种职务，包括国际产品经理（从2000年到2002年）、研究员（从1999年到2000年）产品开发。在Numico之前，Schimmelpennink先生从1998年到1999年担任荷兰国家公共卫生与环境研究所（Dutch National Institute for Public Health and Environment）的疫苗技术专家。Schimmelpennink先生在荷兰瓦赫宁根大学（the Wageningen University）获得生物过程工程硕士学位。
Evert B. Schimmelpennink has served as our Chief Executive Officer, President and Secretary since August 2017 and as our Chief Financial Officer since November 2019. Prior to his appointment, Mr. Schimmelpennink served as the Chief Executive Officer of Alvotech, a biosimilar development company from 2015 to July 2017. From September 2015 to November 2015 Mr. Schimmelpennink served as Vice President-Global Sterile Injectables of Pfizer Inc., a pharmaceutical company. Prior to that, Mr. Schimmelpennink served as Vice President-Global Generics from 2012 to 2015 and Director of Specialty Injectable Pharma Marketing EMEA & Director of Distributor Operations EMEA from 2011 to 2012 of Hospira, Inc., a pharmaceutical company. From 2002 to 2011 Mr. Schimmelpennink held various roles at Synthon BV, a generics medicine company, including Vice President Marketing and Sales from 2008 to 2011. From 1997 to 2002 he held various roles with Numico NV, a Dutch maker of baby foods and nutritional bars and shakes, including International Product Manager from 2000 to 2002 and Researcher Product Development from 1999 to 2000. Prior to Numico, Mr. Schimmelpennink served as a vaccine technologist at the Dutch National Institute for Public Health and the Environment from 1998 to 1999. Mr. Schimmelpennink received a master's in bioprocess engineering from the Wageningen University in the Netherlands. - EvertB.Schimmelpennink自2017年8月起担任我们的首席执行官，总裁兼秘书，自2019年11月起担任我们的首席财务官。在被任命之前，Schimmelpennink先生于2015年至2017年7月担任生物仿制药开发公司Alvotech的首席执行官。2015年9月至2015年11月，Schimmelpennink先生担任制药公司辉瑞公司的Vice President-全球无菌注射剂。在此之前，Schimmelpennink先生于2012年至2015年担任Vice President-Global Generics，并于2011年至2012年担任制药公司好比拉医疗保健公司的特殊注射药物营销EMEA总监和分销商运营EMEA总监。Schimmelpennink从2002年到2011年在Synthon BV（一家仿制药公司）担任多个职位，包括从2008年到2011年担任Vice President市场营销与销售。从1997年到2002年，他曾担任Numico NV公司（荷兰婴儿食品和营养棒和奶昔制造商）的多种职务，包括国际产品经理（从2000年到2002年）、研究员（从1999年到2000年）产品开发。在Numico之前，Schimmelpennink先生从1998年到1999年担任荷兰国家公共卫生与环境研究所（Dutch National Institute for Public Health and Environment）的疫苗技术专家。Schimmelpennink先生在荷兰瓦赫宁根大学（the Wageningen University）获得生物过程工程硕士学位。
- Evert B. Schimmelpennink has served as our Chief Executive Officer, President and Secretary since August 2017 and as our Chief Financial Officer since November 2019. Prior to his appointment, Mr. Schimmelpennink served as the Chief Executive Officer of Alvotech, a biosimilar development company from 2015 to July 2017. From September 2015 to November 2015 Mr. Schimmelpennink served as Vice President-Global Sterile Injectables of Pfizer Inc., a pharmaceutical company. Prior to that, Mr. Schimmelpennink served as Vice President-Global Generics from 2012 to 2015 and Director of Specialty Injectable Pharma Marketing EMEA & Director of Distributor Operations EMEA from 2011 to 2012 of Hospira, Inc., a pharmaceutical company. From 2002 to 2011 Mr. Schimmelpennink held various roles at Synthon BV, a generics medicine company, including Vice President Marketing and Sales from 2008 to 2011. From 1997 to 2002 he held various roles with Numico NV, a Dutch maker of baby foods and nutritional bars and shakes, including International Product Manager from 2000 to 2002 and Researcher Product Development from 1999 to 2000. Prior to Numico, Mr. Schimmelpennink served as a vaccine technologist at the Dutch National Institute for Public Health and the Environment from 1998 to 1999. Mr. Schimmelpennink received a master's in bioprocess engineering from the Wageningen University in the Netherlands.
- Jason Grenfell Gardner
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Magda Marquet
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Lorianne Masuoka
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Phillip M. Schneider
-
Phillip M. Schneider，他被任命为我们的董事，并将加入我们董事会（招股说明书）。最近，他曾担任IDEC Pharmaceuticals Corporation（一家生物制药公司）的多种职务（从1987年到2003年），包括高级副总裁、首席财务官（从1997年到2003年），以及财务和行政董事（从1992年到1997年）。此前，他曾担任Syntex Pharmaceuticals Corporation（一家制药公司）（从1985年到1987年）、毕马威会计事务所（KPMG）（审计和税务咨询公司，在那里他获得注册会计师执照）（从1982年到1984年）的多种管理职务。他目前担任Arena Pharmaceuticals Corporation（医药公司，他于2008年加入该公司）和Auspex Pharmaceuticals公司（制药公司，他于2014年加入该公司）的董事会成员。他此前曾担任Gen-Probe公司（生物技术公司）的董事会成员（从2002年到2012年）。他持有加州大学戴维斯分校（the University of California, Davis）的生物化学学士学位，以及南加利福尼亚大学（the University of Southern California）的工商管理硕士学位。
Phillip M. Schneider has served as a member of our board of directors since December 2020. Most recently, Mr. Schneider held various positions with IDEC Pharmaceuticals Corporation, a biopharmaceutical company, from 1987 to 2003 including, serving as Senior Vice President and Chief Financial Officer from 1997 to 2003. Prior to that, Mr. Schneider held various management positions at Syntex Pharmaceuticals Corporation, a pharmaceutical company, from 1985 to 1987 and KPMG LLP, an audit and tax advisory firm, from 1982 to 1984 where he attained his CPA license. Mr. Schneider currently serves as a member of the board of directors of ARS Pharmaceuticals, Inc, a pharmaceutical company, since June 2019 and YMCA of San Diego County since 2002. Mr. Schneider previously served as a member of the board of directors at Pfenex Inc. from 2014 until its acquisition by Ligand Pharmaceuticals in 2020 Arena from 2007 to 2018 Auspex Pharmaceuticals from 2014 until its acquisition by Teva Pharmaceuticals in 2015 and Gen-Probe, Inc. from 2002 until its acquisition by Hologic Inc. in 2012. Mr. Schneider holds a B.S. in Biochemistry from the University of California, Davis and an M.B.A. from the University of Southern California. - Phillip M. Schneider，他被任命为我们的董事，并将加入我们董事会（招股说明书）。最近，他曾担任IDEC Pharmaceuticals Corporation（一家生物制药公司）的多种职务（从1987年到2003年），包括高级副总裁、首席财务官（从1997年到2003年），以及财务和行政董事（从1992年到1997年）。此前，他曾担任Syntex Pharmaceuticals Corporation（一家制药公司）（从1985年到1987年）、毕马威会计事务所（KPMG）（审计和税务咨询公司，在那里他获得注册会计师执照）（从1982年到1984年）的多种管理职务。他目前担任Arena Pharmaceuticals Corporation（医药公司，他于2008年加入该公司）和Auspex Pharmaceuticals公司（制药公司，他于2014年加入该公司）的董事会成员。他此前曾担任Gen-Probe公司（生物技术公司）的董事会成员（从2002年到2012年）。他持有加州大学戴维斯分校（the University of California, Davis）的生物化学学士学位，以及南加利福尼亚大学（the University of Southern California）的工商管理硕士学位。
- Phillip M. Schneider has served as a member of our board of directors since December 2020. Most recently, Mr. Schneider held various positions with IDEC Pharmaceuticals Corporation, a biopharmaceutical company, from 1987 to 2003 including, serving as Senior Vice President and Chief Financial Officer from 1997 to 2003. Prior to that, Mr. Schneider held various management positions at Syntex Pharmaceuticals Corporation, a pharmaceutical company, from 1985 to 1987 and KPMG LLP, an audit and tax advisory firm, from 1982 to 1984 where he attained his CPA license. Mr. Schneider currently serves as a member of the board of directors of ARS Pharmaceuticals, Inc, a pharmaceutical company, since June 2019 and YMCA of San Diego County since 2002. Mr. Schneider previously served as a member of the board of directors at Pfenex Inc. from 2014 until its acquisition by Ligand Pharmaceuticals in 2020 Arena from 2007 to 2018 Auspex Pharmaceuticals from 2014 until its acquisition by Teva Pharmaceuticals in 2015 and Gen-Probe, Inc. from 2002 until its acquisition by Hologic Inc. in 2012. Mr. Schneider holds a B.S. in Biochemistry from the University of California, Davis and an M.B.A. from the University of Southern California.
高管简历
中英对照 | 中文 | 英文- Evert B. Schimmelpennink
EvertB.Schimmelpennink自2017年8月起担任我们的首席执行官，总裁兼秘书，自2019年11月起担任我们的首席财务官。在被任命之前，Schimmelpennink先生于2015年至2017年7月担任生物仿制药开发公司Alvotech的首席执行官。2015年9月至2015年11月，Schimmelpennink先生担任制药公司辉瑞公司的Vice President-全球无菌注射剂。在此之前，Schimmelpennink先生于2012年至2015年担任Vice President-Global Generics，并于2011年至2012年担任制药公司好比拉医疗保健公司的特殊注射药物营销EMEA总监和分销商运营EMEA总监。Schimmelpennink从2002年到2011年在Synthon BV（一家仿制药公司）担任多个职位，包括从2008年到2011年担任Vice President市场营销与销售。从1997年到2002年，他曾担任Numico NV公司（荷兰婴儿食品和营养棒和奶昔制造商）的多种职务，包括国际产品经理（从2000年到2002年）、研究员（从1999年到2000年）产品开发。在Numico之前，Schimmelpennink先生从1998年到1999年担任荷兰国家公共卫生与环境研究所（Dutch National Institute for Public Health and Environment）的疫苗技术专家。Schimmelpennink先生在荷兰瓦赫宁根大学（the Wageningen University）获得生物过程工程硕士学位。
Evert B. Schimmelpennink has served as our Chief Executive Officer, President and Secretary since August 2017 and as our Chief Financial Officer since November 2019. Prior to his appointment, Mr. Schimmelpennink served as the Chief Executive Officer of Alvotech, a biosimilar development company from 2015 to July 2017. From September 2015 to November 2015 Mr. Schimmelpennink served as Vice President-Global Sterile Injectables of Pfizer Inc., a pharmaceutical company. Prior to that, Mr. Schimmelpennink served as Vice President-Global Generics from 2012 to 2015 and Director of Specialty Injectable Pharma Marketing EMEA & Director of Distributor Operations EMEA from 2011 to 2012 of Hospira, Inc., a pharmaceutical company. From 2002 to 2011 Mr. Schimmelpennink held various roles at Synthon BV, a generics medicine company, including Vice President Marketing and Sales from 2008 to 2011. From 1997 to 2002 he held various roles with Numico NV, a Dutch maker of baby foods and nutritional bars and shakes, including International Product Manager from 2000 to 2002 and Researcher Product Development from 1999 to 2000. Prior to Numico, Mr. Schimmelpennink served as a vaccine technologist at the Dutch National Institute for Public Health and the Environment from 1998 to 1999. Mr. Schimmelpennink received a master's in bioprocess engineering from the Wageningen University in the Netherlands.- EvertB.Schimmelpennink自2017年8月起担任我们的首席执行官，总裁兼秘书，自2019年11月起担任我们的首席财务官。在被任命之前，Schimmelpennink先生于2015年至2017年7月担任生物仿制药开发公司Alvotech的首席执行官。2015年9月至2015年11月，Schimmelpennink先生担任制药公司辉瑞公司的Vice President-全球无菌注射剂。在此之前，Schimmelpennink先生于2012年至2015年担任Vice President-Global Generics，并于2011年至2012年担任制药公司好比拉医疗保健公司的特殊注射药物营销EMEA总监和分销商运营EMEA总监。Schimmelpennink从2002年到2011年在Synthon BV（一家仿制药公司）担任多个职位，包括从2008年到2011年担任Vice President市场营销与销售。从1997年到2002年，他曾担任Numico NV公司（荷兰婴儿食品和营养棒和奶昔制造商）的多种职务，包括国际产品经理（从2000年到2002年）、研究员（从1999年到2000年）产品开发。在Numico之前，Schimmelpennink先生从1998年到1999年担任荷兰国家公共卫生与环境研究所（Dutch National Institute for Public Health and Environment）的疫苗技术专家。Schimmelpennink先生在荷兰瓦赫宁根大学（the Wageningen University）获得生物过程工程硕士学位。
- Evert B. Schimmelpennink has served as our Chief Executive Officer, President and Secretary since August 2017 and as our Chief Financial Officer since November 2019. Prior to his appointment, Mr. Schimmelpennink served as the Chief Executive Officer of Alvotech, a biosimilar development company from 2015 to July 2017. From September 2015 to November 2015 Mr. Schimmelpennink served as Vice President-Global Sterile Injectables of Pfizer Inc., a pharmaceutical company. Prior to that, Mr. Schimmelpennink served as Vice President-Global Generics from 2012 to 2015 and Director of Specialty Injectable Pharma Marketing EMEA & Director of Distributor Operations EMEA from 2011 to 2012 of Hospira, Inc., a pharmaceutical company. From 2002 to 2011 Mr. Schimmelpennink held various roles at Synthon BV, a generics medicine company, including Vice President Marketing and Sales from 2008 to 2011. From 1997 to 2002 he held various roles with Numico NV, a Dutch maker of baby foods and nutritional bars and shakes, including International Product Manager from 2000 to 2002 and Researcher Product Development from 1999 to 2000. Prior to Numico, Mr. Schimmelpennink served as a vaccine technologist at the Dutch National Institute for Public Health and the Environment from 1998 to 1999. Mr. Schimmelpennink received a master's in bioprocess engineering from the Wageningen University in the Netherlands.
- Shawn A. Scranton
ShawnA.Scranton自2018年10月起担任高级副总裁，首席运营官。他此前曾于2017年至2018年担任制药公司Zydus-Cadila的全资子公司Sentynl Therapeutics，Inc.的首席科学顾问。2015年至2017年，Scranton博士担任制药公司Sentynl Therapeutics，Inc.的高级副总裁，首席科学官。任职Sentynl公司之前，Scranton博士曾担任Strategic Therapeutic Solutions，LLC（一家制药咨询公司）的顾问兼董事总经理，并于2007年至2012年担任Victory Pharma，Inc.（一家专业制药公司）的科学运营副总裁。Scranton博士担任Sr.2005年至2007年，担任制药公司Kalypsys，Inc.的转化医学总监，2001年至2005年，担任药物开发公司SalMedix Corporation的临床研究总监/项目总监。Scranton从1998年到2000年担任Dura Pharmaceuticals，Inc.（一家制药公司）临床开发高级临床研究科学家。Scranton博士拥有太平洋大学药学院（University of the Pacific School of Pharmacy）的药学博士学位-1994年和加州大学圣地亚哥分校（University of California，San Diego）的动物生理学学士学位-1988年。
Shawn A. Scranton has served as our Senior Vice President, Chief Operating Officer since October 2018. He previously served as Chief Scientific Consultant for Sentynl Therapeutics, Inc. a wholly owned subsidiarity of Zydus-Cadila, a pharmaceutical company, from 2017 to 2018. From 2015 to 2017 Dr. Scranton served as Senior Vice President, Chief Scientific Officer at Sentynl Therapeutics, Inc., a pharmaceutical company. Prior to Sentynl, Dr. Scranton served as Consultant, Managing Director at Strategic Therapeutic Solutions, LLC, a pharmaceutical consulting company, and from 2007 to 2012 Dr. Scranton served as VP, Scientific Operations at Victory Pharma, Inc., a specialty pharmaceutical company. Dr. Scranton served as Sr. Director of Translational Medicine at Kalypsys, Inc., a pharmaceutical company, from 2005 to 2007 and as Director of Clinical Research/Program Director at Salmedix Corporation, a drug development company, from 2001 to 2005. From 1998 to 2000 Dr. Scranton served as Senior Clinical Research Scientist, Clinical Development at Dura Pharmaceuticals, Inc., a pharmaceutical company. Dr. Scranton holds a Doctor of Pharmacy from the University of the Pacific School of Pharmacy -1994 and a B.A. in Animal Physiology from the University of California, San Diego -1988.- ShawnA.Scranton自2018年10月起担任高级副总裁，首席运营官。他此前曾于2017年至2018年担任制药公司Zydus-Cadila的全资子公司Sentynl Therapeutics，Inc.的首席科学顾问。2015年至2017年，Scranton博士担任制药公司Sentynl Therapeutics，Inc.的高级副总裁，首席科学官。任职Sentynl公司之前，Scranton博士曾担任Strategic Therapeutic Solutions，LLC（一家制药咨询公司）的顾问兼董事总经理，并于2007年至2012年担任Victory Pharma，Inc.（一家专业制药公司）的科学运营副总裁。Scranton博士担任Sr.2005年至2007年，担任制药公司Kalypsys，Inc.的转化医学总监，2001年至2005年，担任药物开发公司SalMedix Corporation的临床研究总监/项目总监。Scranton从1998年到2000年担任Dura Pharmaceuticals，Inc.（一家制药公司）临床开发高级临床研究科学家。Scranton博士拥有太平洋大学药学院（University of the Pacific School of Pharmacy）的药学博士学位-1994年和加州大学圣地亚哥分校（University of California，San Diego）的动物生理学学士学位-1988年。
- Shawn A. Scranton has served as our Senior Vice President, Chief Operating Officer since October 2018. He previously served as Chief Scientific Consultant for Sentynl Therapeutics, Inc. a wholly owned subsidiarity of Zydus-Cadila, a pharmaceutical company, from 2017 to 2018. From 2015 to 2017 Dr. Scranton served as Senior Vice President, Chief Scientific Officer at Sentynl Therapeutics, Inc., a pharmaceutical company. Prior to Sentynl, Dr. Scranton served as Consultant, Managing Director at Strategic Therapeutic Solutions, LLC, a pharmaceutical consulting company, and from 2007 to 2012 Dr. Scranton served as VP, Scientific Operations at Victory Pharma, Inc., a specialty pharmaceutical company. Dr. Scranton served as Sr. Director of Translational Medicine at Kalypsys, Inc., a pharmaceutical company, from 2005 to 2007 and as Director of Clinical Research/Program Director at Salmedix Corporation, a drug development company, from 2001 to 2005. From 1998 to 2000 Dr. Scranton served as Senior Clinical Research Scientist, Clinical Development at Dura Pharmaceuticals, Inc., a pharmaceutical company. Dr. Scranton holds a Doctor of Pharmacy from the University of the Pacific School of Pharmacy -1994 and a B.A. in Animal Physiology from the University of California, San Diego -1988.
- Martin B. Brenner
MartinB.Brenner自2019年3月起担任我们的高级副总裁，首席科学官。2017年至2018年，Brenner博士担任生物技术公司Recursion Pharmaceuticals，Inc.的首席科学官。2016年至2017年，Brenner博士担任生物技术公司StokeTherapeutics，Inc.的Vice President兼研发主管。从2013年到2016年，Brenner博士担任默克制药公司默克研究实验室（Merck Research Laboratories）糖尿病与NASH执行董事兼糖尿病与NASH早期发现部门主席。2012年至2013年，Brenner博士担任制药公司AstraZeneca PLC CVMD的高级董事、生物科学主管。从2009年到2012年，Brenner博士担任制药公司辉瑞公司糖尿病预防和缓解组的副研究员。从2003年到2009年，Brenner博士担任礼来公司（一家制药公司）糖尿病药物搜寻团队的高级研究科学家。Brenner博士拥有德国汉诺威的汉诺威兽医学院（Veterinary School of Hannover）药理学博士学位和德国慕尼黑的路德维希-马克西米利安大学（Ludwig-Maximilians-University）兽医学院的DVM。
Martin B. Brenner,has served as the Company's Chief Executive Officer (CEO) since June 22, 2023, its interim CEO from January 20, 2023 until his appointment as CEO and as the Company's Chief Scientific Officer (CSO) since January 18, 2021. Dr. Brenner was appointed as a member of the Board of Directors on May 9, 2024 effective June 1, 2024. Dr. Brenner has a strong history of success heading drug discovery and development teams at several of the world's leading pharmaceutical companies, including AstraZeneca ("AstraZeneca"), Eli Lilly and Company ("Lilly"), Pfizer Inc.("Pfizer"), and Merck Research Laboratories ("Merck Research Labs"). Most recently, Dr. Brenner served as Senior Vice President, CSO of Pfenex Inc. from March 2019 until its acquisition by Ligand Pharmaceuticals Incorporated in October 2020. From 2017 to 2018, Dr. Brenner served as CSO at Recursion Pharmaceuticals, Inc., a publicly listed biotechnology company. From 2016 to 2017, Dr. Brenner served as Vice President and Head of Research and Early Development at Stoke Therapeutics, Inc., a biotechnology company. From 2013 to 2016, Dr. Brenner served as Executive Director, Diabetes & NASH, and Chair of Diabetes & NASH Early Discovery Unit at Merck Research Lab. From 2012 to 2013, Dr. Brenner served as Senior Director, Head of Bioscience, CVMD at AstraZeneca. From 2009 to 2012, Dr. Brenner served as an Associate Research Fellow for the Diabetes Prevention and Remission Group at Pfizer. From 2003 to 2009, Dr. Brenner served as Senior Research Scientist for the Diabetes Drug Hunting Team at Lilly. Dr. Brenner holds a Ph.D. in Pharmacology from the Veterinary School of Hannover in Hannover, Germany a DVM from Veterinary School of Ludwig-Maximilians-University in Munich, Germany.- MartinB.Brenner自2019年3月起担任我们的高级副总裁，首席科学官。2017年至2018年，Brenner博士担任生物技术公司Recursion Pharmaceuticals，Inc.的首席科学官。2016年至2017年，Brenner博士担任生物技术公司StokeTherapeutics，Inc.的Vice President兼研发主管。从2013年到2016年，Brenner博士担任默克制药公司默克研究实验室（Merck Research Laboratories）糖尿病与NASH执行董事兼糖尿病与NASH早期发现部门主席。2012年至2013年，Brenner博士担任制药公司AstraZeneca PLC CVMD的高级董事、生物科学主管。从2009年到2012年，Brenner博士担任制药公司辉瑞公司糖尿病预防和缓解组的副研究员。从2003年到2009年，Brenner博士担任礼来公司（一家制药公司）糖尿病药物搜寻团队的高级研究科学家。Brenner博士拥有德国汉诺威的汉诺威兽医学院（Veterinary School of Hannover）药理学博士学位和德国慕尼黑的路德维希-马克西米利安大学（Ludwig-Maximilians-University）兽医学院的DVM。
- Martin B. Brenner,has served as the Company's Chief Executive Officer (CEO) since June 22, 2023, its interim CEO from January 20, 2023 until his appointment as CEO and as the Company's Chief Scientific Officer (CSO) since January 18, 2021. Dr. Brenner was appointed as a member of the Board of Directors on May 9, 2024 effective June 1, 2024. Dr. Brenner has a strong history of success heading drug discovery and development teams at several of the world's leading pharmaceutical companies, including AstraZeneca ("AstraZeneca"), Eli Lilly and Company ("Lilly"), Pfizer Inc.("Pfizer"), and Merck Research Laboratories ("Merck Research Labs"). Most recently, Dr. Brenner served as Senior Vice President, CSO of Pfenex Inc. from March 2019 until its acquisition by Ligand Pharmaceuticals Incorporated in October 2020. From 2017 to 2018, Dr. Brenner served as CSO at Recursion Pharmaceuticals, Inc., a publicly listed biotechnology company. From 2016 to 2017, Dr. Brenner served as Vice President and Head of Research and Early Development at Stoke Therapeutics, Inc., a biotechnology company. From 2013 to 2016, Dr. Brenner served as Executive Director, Diabetes & NASH, and Chair of Diabetes & NASH Early Discovery Unit at Merck Research Lab. From 2012 to 2013, Dr. Brenner served as Senior Director, Head of Bioscience, CVMD at AstraZeneca. From 2009 to 2012, Dr. Brenner served as an Associate Research Fellow for the Diabetes Prevention and Remission Group at Pfizer. From 2003 to 2009, Dr. Brenner served as Senior Research Scientist for the Diabetes Drug Hunting Team at Lilly. Dr. Brenner holds a Ph.D. in Pharmacology from the Veterinary School of Hannover in Hannover, Germany a DVM from Veterinary School of Ludwig-Maximilians-University in Munich, Germany.
- Patrick K. Lucy
Patrick K. Lucy，自2009年以来，他一直担任我们的首席商业官。加入我们之前，他曾担任DowPharma公司（从属于The Dow Chemical Company，化学品制造商）的业务发展董事（从2002年到2009年）。从1999年到2002年，他曾担任Collaborative BioAlliance公司（生物技术公司，被The Dow Chemical Company收购）的业务拓展董事。从1998年到1999年，他曾担任验证经理和资本项目经理。从1996年到1998年，他曾担任Lonza Biologics公司（化学和生物技术公司）的生物化学质量控制主管。从1991年到1996年，他曾担任Repligen Corporation（一个生命科学公司）的生物化学质量控制主管。他持有Villanova University的生物学学士学位。
Patrick K. Lucy has served as our Senior Vice President, Chief Business Officer since 2014. Mr. Lucy also served as our Interim Chief Executive Officer, President and Secretary from January 2017 to August 2017 when Mr. Schimmelpennink was appointed to those roles. Mr. Lucy previously served as our Vice President of Business Development and Marketing between 2009 and 2014. Prior to joining us, Mr. Lucy held the position of Director of Business Development at DowPharma, a business within The Dow Chemical Company, a chemicals manufacturer, from 2002 to 2009. From 1999 to 2002 he held the position of Director of Business Development at Collaborative BioAlliance, Inc., a biotechnology company, which was acquired by The Dow Chemical Company. From 1998 to 1999 Mr. Lucy worked as a Validation Manager and Capital Project Manager and from 1996 to 1998 as a Quality Control Biochemistry Supervisor at Lonza Biologics Inc., a chemicals and biotechnology company. From 1991 to 1996 Mr. Lucy held various positions at Repligen Corporation, a life sciences company. Mr. Lucy currently serves on the Scientific Advisory Board of Explorations in Global Health ExGloH a division within the Leidos Health Group. Mr. Lucy holds a bachelor’s degree in Biology from Villanova University.- Patrick K. Lucy，自2009年以来，他一直担任我们的首席商业官。加入我们之前，他曾担任DowPharma公司（从属于The Dow Chemical Company，化学品制造商）的业务发展董事（从2002年到2009年）。从1999年到2002年，他曾担任Collaborative BioAlliance公司（生物技术公司，被The Dow Chemical Company收购）的业务拓展董事。从1998年到1999年，他曾担任验证经理和资本项目经理。从1996年到1998年，他曾担任Lonza Biologics公司（化学和生物技术公司）的生物化学质量控制主管。从1991年到1996年，他曾担任Repligen Corporation（一个生命科学公司）的生物化学质量控制主管。他持有Villanova University的生物学学士学位。
- Patrick K. Lucy has served as our Senior Vice President, Chief Business Officer since 2014. Mr. Lucy also served as our Interim Chief Executive Officer, President and Secretary from January 2017 to August 2017 when Mr. Schimmelpennink was appointed to those roles. Mr. Lucy previously served as our Vice President of Business Development and Marketing between 2009 and 2014. Prior to joining us, Mr. Lucy held the position of Director of Business Development at DowPharma, a business within The Dow Chemical Company, a chemicals manufacturer, from 2002 to 2009. From 1999 to 2002 he held the position of Director of Business Development at Collaborative BioAlliance, Inc., a biotechnology company, which was acquired by The Dow Chemical Company. From 1998 to 1999 Mr. Lucy worked as a Validation Manager and Capital Project Manager and from 1996 to 1998 as a Quality Control Biochemistry Supervisor at Lonza Biologics Inc., a chemicals and biotechnology company. From 1991 to 1996 Mr. Lucy held various positions at Repligen Corporation, a life sciences company. Mr. Lucy currently serves on the Scientific Advisory Board of Explorations in Global Health ExGloH a division within the Leidos Health Group. Mr. Lucy holds a bachelor’s degree in Biology from Villanova University.